Condition: Squamous Cell Carcinoma of the Head and Neck · Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
The investigators want to have a collection of fresh primary or recurrent tumor tissue for establishment of patients-derived xenografts in order to: generate a biobank of in vivo patient xenografts representing the different subgroups of tumors for head and neck cancer * perform genetic and transcriptional profiling of the primary, metastatic tumors and xenograft tumors * evaluate the efficacy of new targeted agents, whether or not in combination with standard treatment options * evaluate biomarkers of drug sensitivity * study primary and secondary (acquired) resistance in these models
This description comes directly from the study's public registry record.
Aline Gillain, MedSciences · 00322764 · aline.gillain@uclouvain.be
Sandra Schmitz, MD, PhD · 00322764 · sandra.schmitz@uclouvain.be
Always discuss trial participation with your own doctor first.
| Cliniques universitaires Saint-Luc | Brussels, Belgium | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02572778